528 related articles for article (PubMed ID: 24727284)
1. Breast cancer stem cells: Multiple capacities in tumor metastasis.
Geng SQ; Alexandrou AT; Li JJ
Cancer Lett; 2014 Jul; 349(1):1-7. PubMed ID: 24727284
[TBL] [Abstract][Full Text] [Related]
2. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis.
Siddharth S; Das S; Nayak A; Kundu CN
Clin Exp Metastasis; 2016 Oct; 33(7):661-75. PubMed ID: 27411340
[TBL] [Abstract][Full Text] [Related]
3. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.
Fritz AJ; Hong D; Boyd J; Kost J; Finstaad KH; Fitzgerald MP; Hanna S; Abuarqoub AH; Malik M; Bushweller J; Tye C; Ghule P; Gordon J; Frietze S; Zaidi SK; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2020 Oct; 235(10):7261-7272. PubMed ID: 32180230
[TBL] [Abstract][Full Text] [Related]
4. Role of microRNAs in the regulation of breast cancer stem cells.
Liu S; Clouthier SG; Wicha MS
J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer stem cell: the roles and therapeutic implications.
Yang F; Xu J; Tang L; Guan X
Cell Mol Life Sci; 2017 Mar; 74(6):951-966. PubMed ID: 27530548
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
Sousa B; Ribeiro AS; Paredes J
Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer.
Qiu Y; Yang L; Liu H; Luo X
Stem Cells; 2021 Sep; 39(9):1125-1136. PubMed ID: 33837587
[TBL] [Abstract][Full Text] [Related]
8. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
9. Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities.
Choi HY; Yang GM; Dayem AA; Saha SK; Kim K; Yoo Y; Hong K; Kim JH; Yee C; Lee KM; Cho SG
Breast Cancer Res; 2019 Jan; 21(1):6. PubMed ID: 30651129
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives.
Chiotaki R; Polioudaki H; Theodoropoulos PA
Curr Cancer Drug Targets; 2015; 15(3):256-69. PubMed ID: 25669721
[TBL] [Abstract][Full Text] [Related]
12. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
Pavlopoulou A; Oktay Y; Vougas K; Louka M; Vorgias CE; Georgakilas AG
Cancer Lett; 2016 Oct; 380(2):485-493. PubMed ID: 27450721
[TBL] [Abstract][Full Text] [Related]
13. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer stem cells: current advances and clinical implications.
Luo M; Clouthier SG; Deol Y; Liu S; Nagrath S; Azizi E; Wicha MS
Methods Mol Biol; 2015; 1293():1-49. PubMed ID: 26040679
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer.
Wang C; Xu K; Wang R; Han X; Tang J; Guan X
J Exp Clin Cancer Res; 2021 Nov; 40(1):370. PubMed ID: 34801088
[TBL] [Abstract][Full Text] [Related]
16. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways governing breast cancer stem cells behavior.
Song K; Farzaneh M
Stem Cell Res Ther; 2021 Apr; 12(1):245. PubMed ID: 33863385
[TBL] [Abstract][Full Text] [Related]
19. Targeting Breast Cancer Stem Cells.
Zhang L; Chen W; Liu S; Chen C
Int J Biol Sci; 2023; 19(2):552-570. PubMed ID: 36632469
[TBL] [Abstract][Full Text] [Related]
20. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
